In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial, semaglutide, a GLP-1 RA, was found to be superior to placebo in reducing risk of a composite major adverse cardiovascular event (MACE) endpoint (consisting of first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke) in participants with established CVD and overweight or obesity but without diabetes [21]
In one 2024 study, high levels of glucose and triglycerides and low levels of high-density lipoproteinwhich are usually signs of worse metabolic healthwere associated with future risk of depression and anxiety ( JAMA Network Open , DOI: 10.1001/jamanetworkopen.2024.4525)
Keep track of all medical bills, including medications, treatments, and specialist visits
We acknowledge that only male mice were used in this study to avoid variability from the female estrous cycle, and therefore sex-specific differences could not be evaluated
UTIs are common, particularly among women, with approximately 5060% of women experiencing at least one UTI during their lifetime
Wegovy is one of the brand names for semaglutide, which is part of a class of drugs that mimic the effects of an appetite-regulating hormone called GLP-1
